Biomedical subjects
David T Feinberg
Publications and source records attributed to David T Feinberg.
Two giant steps forward.
Explore the source record for details and available documents.
The cost of over-the-counter substance abuse.
Explore the source record for details and available documents.
Dr. Robin Hood to cure California's mentally ill.
Explore the source record for details and available documents.
Crossing the health-care quality chasm: When will evidenced-based medicine take hold?
Explore the source record for details and available documents.
Consumer driven health care.
Explore the source record for details and available documents.
"Daddy, what is erectile dysfunction?" Direct-to-consumer advertising will be changing.
Explore the source record for details and available documents.
Are "carve outs" in or out?
Explore the source record for details and available documents.
2002 annual reports: money and pharmaceuticals.
Explore the source record for details and available documents.
Medicare-approved prescription drug discount card program: will this really help our seniors?
Explore the source record for details and available documents.
Quality is in the eye of the beholder.
Explore the source record for details and available documents.
New drugs for the treatment of attention-deficit/hyperactivity disorder.
Attention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric disorder of childhood. Recent research indicates that ADHD most often persists into adolescence and adulthood, and is associated with impairments in academic, social and occupational functioning. The ADHD diagnosis is based on history and clinical examination. There are no objective laboratory measures for diagnosis. ADHD is largely heritable. Its underlying pathophysiology has been theorised to include dysregulation of inhibitory noradrenergic frontocortical activity on dopaminergic striatal structures. Evidence shows that ADHD is highly responsive to pharmacological treatments resulting in global functional improvements. Although pharmacotherapy is recognised as the most effective treatment, additional components to optimise ADHD management include proper educational placement, parent management training and social skills development. Central nervous system stimulants, specifically methylphenidate and amphetamine, remain first-line pharmacological treatments. Atomoxetine, a selective noradrenergic re-uptake inhibitor, is the first non-stimulant compound to receive FDA approval for paediatric and adult ADHD. Other medication classes, including alpha-agonist antihypertensives, tricyclic antidepressants, other antidepressants such as buproprion, and the wake-promoting agent modafinil, are prescribed in off-label therapy. Ongoing development of new ADHD medications is expected to emphasise alternative and extended-release delivery systems and non-stimulant compounds.
Formularies and the like: what managed care companies are doing to keep pharmacy costs down.
Explore the source record for details and available documents.
Opportunity from crisis: how medical cost offset helps our patients and may help save the system.
Explore the source record for details and available documents.
The real cost of pediatric bipolar disorder.
Explore the source record for details and available documents.